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IMPORTANCE For treatment of malignant pleural effusion, nonsteroidal anti-inflammatory
drugs (NSAIDs) are avoided because theymay reduce pleurodesis efficacy. Smaller chest
tubes may be less painful than larger tubes, but efficacy in pleurodesis has not been proven.
OBJECTIVE To assess the effect of chest tube size and analgesia (NSAIDs vs opiates) on pain
and clinical efficacy related to pleurodesis in patients with malignant pleural effusion.
DESIGN, SETTING, AND PARTICIPANTS A 2×2 factorial phase 3 randomized clinical trial among
320 patients requiring pleurodesis in 16 UK hospitals from 2007 to 2013.
INTERVENTIONS Patients undergoing thoracoscopy (n = 206; clinical decision if biopsy was
required) received a 24F chest tube and were randomized to receive opiates (n = 103) vs
NSAIDs (n = 103), and those not undergoing thoracoscopy (n = 114) were randomized to 1 of
4 groups (24F chest tube and opioids [n = 28]; 24F chest tube and NSAIDs [n = 29]; 12F chest
tube and opioids [n = 29]; or 12F chest tube and NSAIDs [n = 28]).
MAINOUTCOMESANDMEASURES Painwhile chest tubewas inplace (0- to 100-mmvisual ana-
log scale [VAS]4 times/d; superiority comparison) andpleurodesis efficacy at 3months (failure
definedasneed for further pleural intervention; noninferiority comparison;margin, 15%).
RESULTS Pain scores in the opiate group (n = 150) vs the NSAID group (n = 144) were not
significantly different (mean VAS score, 23.8mm vs 22.1 mm; adjusted difference, −1.5 mm;
95% CI, −5.0 to 2.0mm; P = .40), but the NSAID group requiredmore rescue analgesia
(26.3% vs 38.1%; rate ratio, 2.1; 95% CI, 1.3-3.4; P = .003). Pleurodesis failure occurred in 30
patients (20%) in the opiate group and 33 (23%) in the NSAID group, meeting criteria for
noninferiority (difference, −3%; 1-sided 95% CI, −10% to; P = .004 for noninferiority). Pain
scores were lower among patients in the 12F chest tube group (n = 54) vs the 24F group
(n = 56) (mean VAS score, 22.0mm vs 26.8mm; adjusted difference, −6.0mm; 95% CI, −11.7
to −0.2 mm; P = .04) and 12F chest tubes vs 24F chest tubes were associated with higher
pleurodesis failure (30% vs 24%), failing to meet noninferiority criteria (difference, −6%;
1-sided 95% CI, −20% to; P = .14 for noninferiority). Complications during chest tube
insertion occurredmore commonly with 12F tubes (14% vs 24%; odds ratio, 1.91; P = .20).
CONCLUSIONS AND RELEVANCE Use of NSAIDs vs opiates resulted in no significant difference
in pain scores but was associated with more rescuemedication. NSAID use resulted in
noninferior rates of pleurodesis efficacy at 3 months. Placement of 12F chest tubes vs 24F
chest tubes was associated with a statistically significant but clinically modest reduction in
pain but failed to meet noninferiority criteria for pleurodesis efficacy.
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T he incidence of malignant pleural effusion is esti-mated to be 150 000 new cases in the United Stateseach year.1,2 To prevent symptoms of breathlessness
and chest pain, removal of pleural fluid by thoracocentesis
and subsequent pleurodesis is advocated in evidence-based
national guidelines such as the 2010 British Thoracic Society
guideline,2,3 with talc being most effective in randomized
trials.3,4
Pleurodesisandchesttubeinsertionarepainful.5-8Mostphy-
sicians use opiates,8 despite nonsteroidal anti-inflammatory
drugs (NSAIDs) being effective in randomized trials of other
causes of acute pain,9 with which pleurodesis pain is prob-
ably comparable. Avoidance of NSAIDs in pleurodesis relates
to concerns that these drugsmay impair long-term fluid con-
trol by suppressing acute inflammation caused by pleurode-
sis agents. An evidence synthesis addressing this question10
identified only 3 reports, all of which were animal models of
pleurodesis. There are no prospective studies of NSAIDs in
pleurodesis in humans, with only supportive data available
from retrospective analysis of pneumothorax pleurodesis.11
The optimal chest tube size for pleurodesis has not been
identified. The British Thoracic Society guideline3 advocates
use of smaller tubes and cites an overall success rate for talc
pleurodesis of 60% to 90%, with 7 of 15 studies cited using
large (20-28 French [F]) tubes. Evidence suggesting that
smaller tubes (<16F) are successful in pleurodesis comes
from case series3 and from 3 comparative studies,12-14 of
which only 1 was randomized,13 and it was not designed to
address pleurodesis noninferiority. In addition, smaller
tubes may be less safe, with 1 observational study reporting
a higher complication rate.15
This pragmatic trial was designed to assess (1) the effect
of NSAIDs comparedwith opiates in treatment of pleurodesis
pain (superiority)andpleurodesisefficacy (noninferiority), and
(2) the effect of small (12F) chest tubes compared with larger
(24F) chest tubes on pain (superiority) and pleurodesis suc-
cess (noninferiority) in a 2×2 factorial, randomized con-
trolled design.
Methods
Study Design
This was a multicenter 2×2 factorial randomized clinical
trial with superiority and noninferiority primary end points.
The study recruited patients across 16 centers (14 in the
United Kingdom, 1 in the United States, and 1 in Canada)
from March 2007 to October 2013 (date of last follow-up).
Ethical and regulatory approval for the study was ob-
tainedbefore recruitmentcommenced,withapproval fromthe
local and regional institutional review boards (the Oxford-
shire Research Ethics Committee and the Medicines and
Healthcare Products Regulatory Agency).
Patients Enrolled
Adults aged 18 years or older were eligible provided they
had a diagnosis of a symptomatic malignant pleural effusion
that was clinically determined to require pleurodesis. Malig-
nant pleural effusions were defined by meeting any 1 of the
following: (1) histocytologically proven pleural malignancy;
(2) typical features of pleural malignancy visualized during
thoracoscopy; or (3) pleural effusion in the context of histo-
logically proven cancer elsewhere.
Patients were ineligible if they had primary lymphoma
or small cell lung carcinoma (due to likely chemosensitivity
and therefore no need for pleurodesis); were pregnant or
lactating; had a history of gastrointestinal bleeding or of
untreated peptic ulceration; had known sensitivity to
NSAIDs or opiates, hypercapnic respiratory failure, current
intravenous drug misuse, severe renal or liver disease,
known bleeding diathesis, or current warfarin therapy; or
were expected to survive less than 1 month.
Allocation to Trial Groups
After written informed consent had been obtained, patients
were randomized to trial group by minimization16 with a
random component using a central telephone service
(United Kingdom Medical Research Council Clinical Trials
Unit at University College London). Minimization criteria
were histological tissue type (mesothelioma vs nonmeso-
thelioma vs unknown), procedure performed (thoracoscopy
vs nonthoracoscopy), and center of recruitment.
The decision to conduct a thoracoscopy was clinical
and based on the need for a diagnostic and therapeutic proce-
dure inasinglesitting.Patientsundergoingthoracoscopy(which
requires a 24F tubepostprocedure)were randomized to either
NSAID or opiate analgesic treatment andwere not included in
the primary analysis of chest tube size outcomes. Patients not
undergoing thoracoscopywere randomized toopiateorNSAID
analgesic treatment and to a 24For 12F chest tube. All patients
wereawareoftreatmentallocations,butoutcomeassessorswere
blinded to the primary outcome of average pain score and to
pleurodesis failure.
All patients received regular background analgesia (acet-
aminophen, 1 g 4 times daily) from the timeof randomization
to chest tubewithdrawal. Patients allocated toNSAID analge-
sia were treated with ibuprofen, 800 mg orally 3 times daily
toamaximumof2.4gper24hours, and thoseallocated toopi-
ate analgesia were treated with oral morphine at a dosage of
10mg4timesdaily,escalating to20mg4timesdaily (ifneeded)
to amaximumof 80mgper 24hours for the duration that the
tube was in situ. If pain continued to an intolerable degree as
judged by the patient despite maximum trial medication,
breakthrough analgesia (intravenous morphine) was permit-
ted in both groups. Pleurodesis was performed according to
written standard operating procedures (eAppendix 9 in
Supplement 1) and was performed using 4 g of sterile high-
grade talc. Patients undergoing talc slurry–based pleurodesis
received intrapleural anesthetic as per current United King-
dom guidelines.3
Trial Outcomes
Primary End Point
The 2 co–primary outcomeswere a superiority comparison of
pain scores and a noninferiority comparison of the occur-
rence of pleurodesis failure.
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Pain | The primary outcome for pain was mean pain score
while the chest tube was in situ (up to 5 days), measured
using a participant-completed 100-mm visual analog scale
(VAS)9 4 times per day (at 8 AM, 12 PM, 4 PM, and 8 PM), with
0 mm indicating no pain and 100 mm indicating worst pain
ever experienced. The published minimum clinically signifi-
cant threshold for a 100-mm VAS pain score is 13 mm (95%
CI, 10-16 mm).17 A mean pain score was calculated using all
VAS measurements from randomization until tube removal.
Patients were permitted rescue medication as needed and
completed an extra VAS assessment prior to taking any res-
cue medication; this was accounted for in the analysis by
assuming that the “rescue” VAS measurement would have
continued until the next scheduled VAS assessment. Visual
analog scale scores were measured by 2 independent
observers blinded to treatment group, with a protocol for
resolving discrepant scores.
Pleurodesis Failure at 3 Months | Patients were classified as hav-
ing pleurodesis failure if they required a further pleural
intervention for relief of breathlessness on the same side as
the pleurodesis in the 3 months after randomization. To
reduce bias, the trial protocol allowed those with symptoms
and a chest radiograph demonstrating 50% or more of the
hemithorax occupied by fluid to have a further pleural inter-
vention. Patients with symptoms and less than 50% of
hemithorax occupied by fluid were referred for further pleu-
ral intervention only if the attending clinician discussed the
case with a second clinician blinded to treatment group and
consensus was reached regarding further treatment.
Secondary End Points
Secondary outcomes included change in pain over time; time
to pleurodesis failure 6 months after randomization; pain
scores at 4 and 12weeks after randomization; volumeof pleu-
ral fluid drained while the tube was in situ; number of times
rescue medication was taken during the hospital stay; all-
causemortality up to 12months; proportion of complications
occurring during insertion of the chest tube; safety outcomes
(including change from baseline to day 2 in hemoglobin, re-
nalmeasures, and liver function); and frequencyof seriousand
nonserious adverse events.
Statistical Analysis
Power Calculations
Sample size calculationswereperformed forbothprimaryout-
comes, and the oneproviding the larger sample sizewas used
as the basis for the study. The larger sample size calculation
related to thenoninferioritycomparisonof thepleurodesis fail-
ure outcome.
Based on an acute pain trial comparing opiateswith high-
doseNSAIDsusing similarmethods,18whichdemonstratedan
effect size of 7.2 (SD, 6.1), a total of 36 patients were required
to demonstrate superiority in a factorial design (90% power;
α = .05; 10% not assessable).
For the noninferiority comparison of pleurodesis fail-
ure, talc pleurodesis was estimated to have a 20% failure at
3 months on the basis of previous randomized data on talc
pleurodesis in malignant pleural effusion (summarized in
evidence-based guidelines3). The acceptable margin of non-
inferiority of pleurodesis failure was based on clinical opin-
ion and set at −15% based on a survey of 10 UK respiratory
physicians who regularly provide care for patients with
malignant pleural effusion. Using this margin with 90%
power and 1-sided 5% significance and assuming 10% of
patients would not be assessable, 320 patients were
required to be randomized. Full details of statistical meth-
ods and other treatments are presented in Supplement 2
and Supplement 3.
Data Analysis
A complete statistical analysis plan was written and ap-
provedprior todatabase lock (Supplement3).All analyseswere
preplanned per the trial protocol (Supplement 2).
Mean pain scores (superiority comparison) were ana-
lyzed by intention to treat (ITT), including all randomizedpa-
tientswithat least 1 recordedpostrandomizationVASscoreand
using multiple imputation. Treatment groups were com-
pared for noninferiority of pleurodesis failure in both the ITT
and per-protocol populations (preplanned). The ITT analysis
included all randomizedpatients forwhomapleurodesis fail-
ure outcome was available and the per-protocol analysis in-
cluded all randomizedpatientswhohad a chest tube inserted
and received talc. Patients who died but did not require fur-
therdrainagewerenotclassifiedashaving failures;deathswere
accountedfor inananalysisofcompetingriskagainstpleurode-
sis failure (see Supplement 3 for full definitions). Noninferi-
ority was assessed using the lower bound only of the 1-sided
95% Wald confidence interval. All superiority analyses were
2-sided at the 5% level.
Because only patients not undergoing thoracoscopy
were randomized to 24F vs 12F chest tubes, only nonthora-
coscopy patients were included in the primary comparison
of tube size for each outcome. A secondary comparison was
made of 24F vs 12F chest tubes including all thoracoscopy
and nonthoracoscopy patients. The groups receiving opiates
and 24F chest tubes were considered the controls for all
analyses.
An initial interaction test was conducted between drain
size and analgesia for both primary outcomes. Multiple
imputation was used to account for missing data for both
outcomes. The average pain score was analyzed using a
mixed-effects linear regression model with adjustment for
minimization variables (histological tissue type, thoraco-
scopic procedure, and center). The absolute difference in
the proportion of patients who had pleurodesis failure was
calculated using a generalized linear model with a binomial
family and identity link. Because of potential overstratifica-
tion, minimization variables were not adjusted for.19 Sensi-
tivity analyses of the primary outcome were performed to
test the robustness of the results, not accounting for rescue
medication (pain), logistic regression and competing risks
(pleurodesis failure), and with respect to missing data under
a number of data “missing not at random” assumptions
(Supplement 3). A secondary analysis was conducted suit-
able to a 4-group trial (Supplement 3).
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Linear mixed-effects models with a random effect for
center were used to assess continuous variables, and logistic
regression was used for binary outcomes where appropri-
ate. The number of times rescue medication was taken dur-
ing a hospital stay was analyzed using negative binomial
regression. Time to pleurodesis failure during the first 6
months after randomization was analyzed using competing
risks. All analyses were conducted using Stata software, ver-
sion 12.1 (Stata Corp).
Results
Patients
The trial flow diagram is presented in Figure 1. A total of 320
patients were recruited to the trial, of whom 201 (62.8%)
were men; with a mean age of 71.8 years; and of whom 122
(38%) had effusion from metastatic cancer including lung; 9
(2.8%) had mesothelioma and 189 (59%) had malignancy
identified at thoracoscopy, with histology taken at the time
of thoracoscopy. A total of 160 patients were randomized to
receive opiates and 160 to receive NSAIDs. Of 114 patients
undergoing a nonthoracoscopic procedure, 57 were ran-
domized to 12F and 57 to 24F chest tubes. Interaction tests
were nonsignificant (P = .49 for pain score; P = .31 for
pleurodesis failure), permitting factorial analysis for all out-
comes. Baseline demographic and clinical characteristics of
patients were similar in all treatment groups (Table 1), with
the exception of an excess of men in the 24F chest tube
group. The baseline pleural opacity occupied by the malig-
nant pleural effusion on chest radiograph was similar across
all groups.
Data Quality
The primary outcome measure for pain was available in 308
(96%) of 320 patients, and pleurodesis outcomes were avail-
able in 297 (93%) of 320 and 264 (83%) of 320 at 1 and 3
months following randomization, respectively (294 patients
were included in the primary analysis) (Figure 1). During the
first 3 months after randomization, 79 (25%) of the 320
Figure 1. Flow of Patients Through the TIME1 Trial
98 Included in primary
analysis of analgesia
for pain
5 Excluded
2 Chest tube not
inserted
3 No VAS score
96 Included in primary
analysis of analgesia
for pain
7 Excluded
2 Chest tube not
inserted
5 Pleurodesis loss
100 Included in primary
analysis of analgesia
for pain
3 Excluded
1 Chest tube not
inserted
2 No VAS score
98 Included in primary
analysis of analgesia
for pain
5 Excluded
1 Chest tube not
inserted
4 Pleurodesis loss
27 Included in primary
analysis of analgesia
and chest tube size
for pain
1 Excluded (chest tube
not inserted)
23 Included in primary
analysis of analgesia
and chest tube size
for pleurodesis
5 Excluded
1 Chest tube not
inserted
4 Pleurodesis loss
27 Included in primary
analysis of analgesia
and chest tube size
for pain
27 Included in primary
analysis of analgesia
and chest tube size
for pleurodesis
2 Excluded
1 Chest tube not
inserted
1 Pleurodesis loss
2 Excluded
1 Chest tube not
inserted
1 No VAS score
28 Included in primary
analysis of analgesia
and chest tube size
for pain
1 Excluded (chest tube
not inserted)
25 Included in primary
analysis of analgesia
and chest tube size
for pleurodesis
4 Excluded
1 Chest tube not
inserted
3 Pleurodesis loss
28 Included in primary
analysis of analgesia
and chest tube size
for pain
25 Included in primary
analysis of analgesia
and chest tube size
for pleurodesis
3 Excluded (pleurodesis
loss)
103 Randomized to
receive 24F chest
tube and NSAIDs
101 Received
intervention as
randomized
2 Excluded (chest
tube not
inserted)
103 Randomized to
receive 24F chest
tube and opiates
102 Received
intervention as
randomized
1 Excluded (chest
tube not
inserted)
28 Randomized to
receive 12F chest
tube and NSAIDs
27 Received
intervention as
randomized
1 Excluded (chest
tube not
inserted)
29 Randomized to
receive 12F chest
tube and opiates
28 Received
intervention as
randomized
1 Excluded (chest
tube not
inserted)
29 Randomized to
receive 24F chest
tube and NSAIDs
28 Received
intervention as
randomized
1 Excluded (chest
tube not
inserted)
28 Randomized to
receive 24F chest
tube and opiates
28 Received
intervention as
randomized
528 Excluded
848 Patients screened
320 Patients eligible and provided
informed consent
206 Had thoracoscopic procedure
and were randomized
114 Had nonthoracoscopic procedure
and were randomized
NSAIDs indicates nonsteroidal anti-inflammatory drugs. Patients were
simultaneously randomized to chest tube size and analgesia regimen in the
nonthoracoscopic group. Reasons for screening failure were not recorded but
included ineligibility and patient refusal. No VAS score refers to patients who did
not complete a single visual analog scale assessment and pleurodesis loss refers
to patients in whom data on pleurodesis efficacy was not available at follow-up.
A total of 6 patients did not have chest tubes inserted.
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Table 1. Baseline Characteristics of the 320 Participants
Characteristics
Chest Tube Size Analgesia
24F
(n = 263)
12F
(n = 57)
Opiates
(n = 160)
NSAIDs
(n = 160)
Demographics
Female, No. (%) 84 (32) 35 (61) 58 (36) 61 (38)
Age,
mean (SD), y
72.1 (10.0) 70.4 (11.9) 72.6 (9.9) 71.0 (10.8)
Diagnosis
at baseline
(minimization
criteria),
No. (%)
Mesothelioma 6 (2) 3 (5) 3 (2) 6 (4)
Nonmesothelioma 74 (28) 48 (84) 58 (36) 64 (40)
Unknown at time
of procedure
183 (70) 6 (11) 99 (62) 90 (56)
Thoracoscopic
procedure,
No. (%)
Yes 206 (78) 0 103 (64) 103 (64)
No 57 (22) 57 (100) 57 (36) 57 (36)
Pleurodesis and pain,
No. (%)
Received analgesia
in last 3 mo
111 (42) 33 (58) 67 (42) 77 (48)
Oral steroid use
in last mo
24 (9) 11 (19) 18 (11) 17 (11)
Previous
pleurodesis
11 (4) 7 (12) 12 (8) 6 (4)
Previous
thoracocentesis
138 (52) 29 (51) 84 (53) 83 (52)
Visual analog
scale score,
median (IQR)
Pain at baseline 3.5 (1-10.3) 10 (2.7-21.5) 4.0 (1.3-16) 4.0 (1.0-10.0)
Pain having
cannula inserted
4.8 (2-13) 7.5 (2-19) 4.8 (2-13.6) 5 (1.8-13.5)
Baseline
pleural opacity,
mean (SD), %
hemithorax
occupied on chest
radiographa
43.4 (24.4) 51.6 (25.8) 44.0 (24.3) 45.9 (25.4)
Comorbidities,
No. (%)
Arthritis 42 (16) 11 (19) 30 (19) 23 (14)
Respiratory 53 (20) 12 (21) 35 (22) 30 (19)
Cardiac 101 (38) 26 (46) 55 (34) 72 (45)
Liver 11 (4) 3 (5) 6 (4) 8 (5)
Gastroesophageal 46 (17) 10 (18) 25 (16) 31 (19)
Excessive alcohol
intakeb
7 (3) 1 (2) 5 (3) 3 (2)
Immunosuppression 7 (3) 0 6 (4) 1 (1)
Renal 9 (3) 4 (7) 8 (5) 5 (3)
Diabetes 29 (11) 7 (12) 20 (13) 16 (10)
Neurological/
mental disability
13 (5) 4 (7) 8 (5) 9 (6)
Psychiatric 5 (2) 2 (4) 1 (1) 6 (4)
Other 73 (28) 21 (37) 45 (28) 49 (31)
(continued)
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patients died. Mortality data were available for all patients
at 12 months. For details on data quality, see eAppendix 1 in
Supplement 1.
Primary End-Point Analysis
Therewas no significant difference inmean pain scores com-
paring NSAIDs with opiates while the chest tube was in place
(mean VAS score in the NSAID group, 22.1 mm [SD, 16.9 mm]
vs in the opiate group, 23.8 mm [SD, 15.8 mm]; adjusted dif-
ference in means, −1.5 mm; 95% CI, −5.0 to 2.0; P = .40)
(Table 2). Rescue analgesia was used more frequently in the
NSAID group (number of patients requiring rescue medica-
tion in theNSAIDgroup, 61/160 [38.1%] vs in theopiate group,
42/160 [26.3%]; rate ratio, 2.1; 95%CI, 1.3-3.4; P = .003), with
a low median number of doses per participant (interquartile
range, 0-1).
There was significantly less pain with smaller vs larger
tubes (mean VAS scores, 22.0 mm [SD, 16.6 mm] vs 26.8 mm
[SD, 16.9 mm], respectively; adjusted difference in means,
−6.0 mm; 95% CI, −11.7 to −0.2 mm; P = .04) (Table 2).
There was no significant difference in the amount of rescue
analgesia required according to tube size (rate ratio, 1.1; 95%
CI, 0.38-3.18; P = .86). The difference in pain scores
remained when analysis was repeated not accounting for
use of rescue medication (mean VAS score for 12F tubes,
21.3 mm [SD, 15.8 mm]); for 24F tubes, 25.8 mm [SD, 16.9
mm]; adjusted difference in means, −5.6 mm; 95% CI, −11.2
to 0.02 mm; P = .05).
In the ITT analysis for pleurodesis failure at 3 months,
NSAIDs met prespecified criteria for noninferiority because
the lower bound of the 1-sided 95% confidence interval
did not cross the 15% margin (failure rate: opiates, 30/150
(20.0%); NSAIDs, 33/144 (22.9%); difference, −3%; 95% CI,
−10% to ). Smaller chest tubes had a higher failure rate (24F
tubes, 12/50 [24.0%]; 12F tubes, 15/50 [30.0%]; difference,
−6%; 95% CI, −20% to ) (Table 2 and Figure 2), failing to
meet the 15% margin of noninferiority. The more stringent
97.5% confidence interval for pleurodesis failure gave similar
results (Table 2). Including all patients (with andwithout tho-
racoscopy; preplanned secondary analysis) comparing tube
size for pleurodesis failure, there remained an increased rate
of pleurodesis failure using smaller tubes (failure rate: 24F
tubes, 48/244 [19.7%]; 12F tubes, 15/50 [30.0%]; difference,
−10%; 95% CI, −21% to ). The per-protocol analyses demon-
strated similar results for pleurodesis failure (Figure 2 and
eAppendix 8 in Supplement 1).
Details ofhowpatientsmet thecriteria forpleurodesis fail-
ure are given in eAppendix 9 in Supplement 1.
Table 1. Baseline Characteristics of the 320 Participants (continued)
Characteristics
Chest Tube Size Analgesia
24F
(n = 263)
12F
(n = 57)
Opiates
(n = 160)
NSAIDs
(n = 160)
Baseline laboratory
measurements,
mean (SD)
Hemoglobin, g/dL 13.5 (1.8) 12.7 (1.8) 13.2 (1.7) 13.5 (2.0)
White blood cell
count, /μL
8900 (3000) 9100 (2500) 9000 (3100) 8900 (2800)
Platelet count,
103/μL
333 (114) 340 (115) 333 (114) 336 (115)
Prothrombin
time, s
13.9 (5.5) 14.9 (6.6) 13.8 (5.9) 14.5 (5.5)
aPTT, s 26.6 (8.0) 23.8 (6.9) 25.8 (8.3) 26.4 (7.5)
Albumin, g/dL 3.8 (0.6) 3.6 (0.6) 3.7 (0.6) 3.8 (0.7)
C-reactive protein,
median (IQR),
mg/L
26 (8-62) 28 (14-64) 28.5 (9-65) 26 (9-57)
Creatinine, mg/dL 0.97 (0.27) 0.93 (0.29) 0.98 (0.27) 0.95 (0.28)
Alanine
aminotransferase,
U/L
25 (15) 32 (29) 26 (19) 26 (17)
Alkaline
phosphatase,
median (IQR), U/L
105 (81-158) 113 (86-144) 100 (82-150) 113 (81-158)
Urea nitrogen,
mg/dL
16.8 (9.2) 18.8 (8.1) 17.4 (6.7) 17.1 (11.2)
Respiratory
rate, /min
18 (3) 18 (2) 18 (3) 19 (4)
Oxygen
saturation, %
95 (3) 94 (3) 95 (3) 95 (3)
Blood pressure,
mm Hg
Systolic 133 (18) 129 (17) 133 (18) 132 (19)
Diastolic 78 (12) 76 (12) 77 (12) 78 (12)
Abbreviations: aPTT, activated
partial thromboplastin time;
IQR, interquartile range;
NSAIDs, nonsteroidal
anti-inflammatory drugs;
VAS, visual analog scale.
a Radiological score derived from
digital measurement of chest
radiographs by previously
establishedmethods.20
bExcessive alcohol intake was
defined as a formal clinician
diagnosis of alcohol excess
in the patient’s medical notes
or patient reported dependence
on alcohol currently.
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Subgroup Analyses
Therewasnoevidenceof adifferential treatment effect in any
subgroupsanalyzed forpainorpleurodesis failure ineither an-
algesic regimen or tube size comparisons (P > .10 for all inter-
action tests; data presented in eAppendix 2 in Supplement 1).
Secondary End-Point Results
Change in Pain Over Time
Figure 3 showschanges inpain scoresover time following ran-
domization by treatment group. Over time, there was a non-
significant reduction in pain comparing NSAIDs with opiates
and a reduction in pain using 12F chest tubes compared with
24F chest tubes.
Time FromRandomization to Pleurodesis Failure
Patients treated with opiates had a shorter time to pleurode-
sis failure compared with those treated with NSAIDs, but
this did not reach statistical significance (time to pleurode-
sis failure: opiates, 48.9 days [SD, 46.3 days]; NSAIDs, 73.0
days [SD, 66.5 days]; hazard ratio, 1.1; 95% CI, 0.7-1.8;
P = .69). Patients treated with a 12F chest tube had a shorter
time to pleurodesis failure vs those treated with a 24F chest
tube, but this also did not reach statistical significance (time
to pleurodesis failure: 12F tubes, 31.6 days [SD, 20.3 days],
24F tubes, 61.3 days [SD, 57.8 days]; hazard ratio, 1.2; 95%
CI, 0.6-2.5; P = .64). Kaplan-Meier data on time to pleurode-
sis failure censored for death are presented in Figure 4.
Pain Scores at 1 and 3Months After Randomization
Pain scores at 1 month were not significantly different by
analgesia and chest tube size groups (difference, −1.0 mm;
Figure 2. Noninferiority Comparison for Pleurodesis Failure
by Treatment Comparisons (Analgesia and Tube Size)
Using Intention-to-Treat (ITT) and Per-Protocol Analysis
–20 0–5
Absolute Difference in Pleurodesis
Failure, % (1-sided 95% CI)
5–10–15
Favors
control
No. of Patients
OpiatesAnalgesia NSAIDs
150 144ITT
140 137Per protocol
24FChest tube 12F
50 50ITT
46 42Per protocol
The prespecified noninferiority margin was set at −15% for pleurodesis failure
and only the lower bound of the interval was used to assess noninferiority. The
shaded area represents the zone of noninferiority. The control group for
analgesia is opiates and the control group for chest tube size is 24F.
Table 2. Primary andMajor Secondary Outcomes: Factorial Comparison of Treatment Groups
Outcome Measures
by Treatment Group
No. of
Patients
Analyzed Outcomes Treatment Effect (95% CI) P Value
VAS pain score while tube in situ, to
5 d (superiority; ITT)
Chest tube size
24F 56 26.8 (16.9)a
−6.0 (−11.7 to −0.2)a .04
12F 54 22.0 (16.6)a
Analgesia
Opiates 155 23.8 (15.8)a
−1.5 (−5.0 to 2.0)a .40
NSAIDs 153 22.1 (16.9)a
Pleurodesis failure at 3 mo
(noninferiority; ITT)b
Chest tube size
24F 50 12 (24)c
−6 (−20 to )c,d,e .14f
12F 50 15 (30)c
Analgesia
Opiates 150 30 (20)c
−3 (−10 to )c,g,h .004f
NSAIDs 144 33 (23)c
Secondary comparison of primary
outcomes (all chest tubes,
thoracoscopic and
nonthoracoscopic; ITT)
VAS pain score while tube in situ,
to 5 days (superiority)
Chest tube size
24F 254 23.2 (16.3)a
−5.6 (−11.4 to 0.2)a .06
12F 54 22.0 (16.6)a
Pleurodesis failure at 3 mo
(noninferiority; ITT)
Chest tube size
24F 244 48 (20)c
−10 (−21 to )c,d,i .24f
12F 50 15 (30)c
Abbreviations: ITT, intention
to treat; NSAIDs, nonsteroidal
anti-inflammatory drugs; VAS, visual
analog scale.
a Pain outcomes reported as mean
(SD) score in millimeters on the VAS
pain scale; treatment effect
measured as mean difference in
pain scores.
b Patients were classified as having
pleurodesis failure if they required a
further pleural intervention for relief
of breathlessness on the same side
as the pleurodesis in the 3months
after randomization.
c Pleurodesis failure outcomes
reported as No. (%) of participants;
treatment effect measured as
percentage risk difference.
d Fails to meet noninferiority margin,
preset at −15%.
e One-sided 97.5% CI is −23%; fails to
meet the noninferiority margin.
f P value for noninferiority (1-sided
test). Pain primary outcome analysis
was adjusted for baseline pain score
and theminimization variables.
g Meets noninferiority criteria.
hOne-sided 97.5% CI is −12% to;
meets the noninferiority criteria.
i One-sided 97.5% CI is −24%; fails to
meet the noninferiority margin.
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95% CI, −6.4 to 4.4 mm; P = .72 for analgesia groups and dif-
ference, 7.7mm;95%CI, −3.3 to 18.6mm;P = .17 for chest tube
groups).Resultswere similar for bothanalgesia andchest tube
size groups at 3 months (Table 3).
Volume of Pleural Fluid Drained
and 3-Month Radiological Outcomes
Neither thevolumeofpleural fluiddrainednor theareaofchest
radiographicopacityat 1 and3monthsafter randomizationdif-
fered significantly between tube size or analgesia treatment
groups (Table 3).
All-CauseMortality to 12Months
Mortality rateswerenot significantlydifferentbetween thean-
algesia groups (NSAIDs, 98/160 [61.3%]; opiates, 86/160
[53.8%]; adjustedodds ratio, 1.5; 95%CI,0.9-2.3;P = .11) or be-
tweenthechest tubesizegroups (12F tubes,40/57 [70.1%];24F
tubes, 43/57 [75.4%]; adjusted odds ratio, 1.4; 95% CI, 0.6-
3.3; P = .48).
Adverse Events
Therewasnodifference inseriousornonseriousadverseevents
between the chest tube size and analgesia groups (Table 4).
Therewasanonsignificantexcessof complicationsduring tube
insertion in the 12F tube group (24%) comparedwith the 24F
tube group (14%; adjusted odds ratio, 1.9; 95% CI, 0.7-5.1;
P = .20).Moderate or severe adverse events occurred in 18pa-
tients in both the 12F and 24F tube groups and in 28 patients
in both the NSAID and opiate groups (eAppendix 6 in
Supplement 1). Safety bloodmeasurements comparing base-
Figure 3. Pain Trends Over Time After Chest Tube Insertion by Randomized Group
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Mean scores (error bars indicate SDs)
are shown for each time point at
which the visual analog scale (VAS)
for pain was administered. Panel A
compares pain scores between the
control group (opiates) and patients
receiving nonsteroidal
anti-inflammatory drugs (NSAIDs);
panel B compares pain scores
between the control group (24F
chest tubes) and patients receiving
12F chest tubes. Median numbers of
patients contributing to the analysis
were, for opiates, 89 (range, 8-148);
NSAIDs, 84 (range, 5-149); 12F chest
tubes, 40 (range, 5-52); and 24F
chest tubes, 46 (range, 6-56). For
details on the number of patients
who contributed at each time point,
see eAppendix 7 in Supplement 1.
IQR indicates interquartile range.
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line to day 2 after randomization were not significantly dif-
ferent between the treatment groups, with the exception of
change in blood creatinine levels,whichwere statistically sig-
nificantly elevated in the NSAID group but by a clinically in-
significant margin (9 μmol/L adjusted difference in means;
Table 5). There were no differences in the time the tube was
in situ or the time spent in the hospital between the groups
(eAppendix 5 in Supplement 1).
Adherence to Trial Interventions
Thenumberofpatients in the trialwitha successful chest tube
insertionwashigh anddidnot differ among treatment groups
(12F tubes, 55/57 [96%]; 24F tubes, 56/57 [98%]; opiates,
158/160 [99%];NSAIDs, 156/160 [98%]). Theproportionofpa-
tients with a successful chest tube insertion and who re-
ceived talcdidnotdifferbyanalgesic regimen (opiates, 146/158
[92.4%]; NSAIDs, 147/156 [94.2%]) but did differ by tube size
(12F tubes, 44/55 [80%]; 24F tubes, 52/56 [92.9%]). Smaller
tubes were dislodged (before a clinical decision to remove)
more frequently than larger tubes (12F tubes, 24/57 [42%]; 24F
tubes, 74/263 [28%]).
Discussion
This trial is the largest study to our knowledge to specifi-
cally address analgesia and tube size for malignant pleural
effusion pleurodesis in terms of pain experienced and
pleurodesis success. The results challenge a number of
assumptions about the optimal chest tube size and analge-
sic strategy for malignant pleural effusion pleurodesis and,
by implication, current evidence-based guidelines such as
the British Thoracic Society guideline, undertaken using
SIGN methods.3
This study demonstrated that NSAIDs are not superior
to opiates in the management of pain after tube insertion
and pleurodesis. However, given in high doses for a short
period, NSAIDs given after talc pleurodesis were safe, effec-
tive, and not inferior in terms of pleurodesis efficacy.
Although NSAID use was associated with increased use of
rescue medication compared with an opiate-based strategy
in 12% of patients requiring a small number of doses, the
resultant pain experienced was not significantly different
between opiate-treated and NSAID-treated patients. The
increased requirement for rescue analgesia in the NSAID
group may be a result of these drugs providing less pain
relief than opiates. However, the finding of the same mean
pain scores in the opiate and NSAID groups, whether rescue
analgesia was accounted for or not, may reflect the
unblinded nature of the trial, with the potential for NSAID-
treated patients to have had a greater perception of the need
for rescue analgesia. These data suggest that NSAIDs can be
used in patients undergoing pleurodesis if required. Also, in
this study, despite the mean age of 71 years among partici-
pants, short-term use of high-dose NSAIDs was not associ-
ated with significant renal impairment or gastrointestinal
adverse effects.
This trial also demonstrates that smaller (12F) chest tubes
are associated with less pain than larger (24F) tubes. Al-
though this difference was statistically significant and con-
sistent (whether rescue analgesia was accounted for or not),
the absolute difference in pain scores between smaller and
larger tubes on average was small (6 mm) and was below the
published minimum clinically significant threshold for a
100-mm VAS pain score (13 mm; 95% CI, 10-16 mm).17 Thus,
there is relatively little clinicalbenefit in termsof lesspain from
use of smaller chest tubes for malignant pleural effusion
pleurodesis.
However, the results of this trial also demonstrate that
smaller chest tubes may be inferior to larger chest tubes in
terms of pleurodesis success, given a 15% margin of nonin-
feriority. Although many previous case series and small
Figure 4. Time to Pleurodesis Failure Between Randomization and 6Months by Tube Size and Analgesia Strategy, Censored for Loss
to Follow-up and Death
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comparative studies have suggested that smaller chest
tubes are “as good as” larger ones for malignant effusion
pleurodesis,2,3 this is the first randomized study to our
knowledge to specifically address this question using a non-
inferiority design. As a consequence of including thoracos-
copy cases, for which only large-bore tubes are used, num-
bers of patients in the direct comparison of small-bore and
large-bore tubes was limited; however, in this comparison,
small tubes failed to meet noninferiority criteria, although
this study was underpowered for this outcome because of
the high number of patients undergoing thoracoscopies
recruited to the study. On the basis of these data, perform-
ing a pleurodesis using a small tube according to current
national guidelines2,3 may reduce the likelihood of
pleurodesis success compared with larger-bore tubes. Fur-
thermore, larger direct comparison studies of small- and
large-bore chest tubes are now required, but the current
study poses important questions as to whether small-bore
chest tubes are truly as efficacious as large-bore tubes for
malignant pleural effusion pleurodesis.
The potential reasons for the 6% observed decrease in
successful pleurodesis may include incomplete drainage; an
increased unintentional displacement rate, thereby prevent-
ing adequate drainage after pleurodesis; and an increase in
the frequency of patients unable to receive talc intrapleu-
rally because of blockage of smaller tubes. Our data demon-
strate that patients treated with smaller tubes were able to
receive talc less often (80% vs 93%) and had a higher fre-
quency of unintentional displacement of the chest tube
(42% vs 28%). This is further supported by the slightly dif-
Table 3. Secondary Outcomesa
Outcome Measures by Treatment
Group
No. of Patients
Analyzed Outcomes
Treatment Effect, Mean
Difference (95% CI) P Value
Volume of pleural fluid drained
while tube in situ (ITT)
Chest tube size
24F 55 3086 (1822)b
−241 (−878 to 397) .46
12F 55 2879 (2074)b
Analgesia
Opiates 155 2733 (1726)b
190 (−190 to 571) .33
NSAIDs 154 2891 (1931)b
Chest radiograph opacity
at 1 mo (ITT)
Chest tube size
24F 34 25.2 (17.9)c
−3.5 (−3.7 to 10.8) .34
12F 30 28.2 (18.2)c
Analgesia
Opiates 100 26.0 (18.5)c
−1.2 (−5.9 to 3.5) .62
NSAIDs 99 25.3 (18.1)c
Chest radiograph opacity
at 3 mo (ITT)
Chest tube size
24F 20 18.9 (17.0)c
6.2 (−2.9 to 15.4) .18
12F 23 27.7 (23.9)c
Analgesia
Opiates 69 25.1 (20.9)c
−2.0 (−7.8 to 3.8) .50
NSAIDs 65 21.9 (19.1)c
VAS pain score at 1 mo (ITT)
Chest tube size
24F 32 3 (13-26)d
7.7 (−3.3 to 18.6) .17
12F 32 6 (1-48)d
Analgesia
Opiates 117 7 (2-19)d
−1.0 (−6.4 to 4.4) .72
NSAIDs 100 4 (2-18)d
VAS pain score at 3 mo (ITT)
Chest tube size
24F 25 5 (2-20)d
−7.7 (−18.4 to 3.0) .16
12F 21 4 (2-20)d
Analgesia
Opiates 96 6 (1-23)d
−1.3 (−6.2 to 3.6) .60
NSAIDs 88 5 (1-18)d
Abbreviations: ITT, intention to treat;
NSAIDs, nonsteroidal
anti-inflammatory drugs; VAS, visual
analog scale.
a Pain outcome analysis was adjusted
for baseline pain score and the
minimization variables. Pleural fluid
and x-ray outcomes were adjusted
for baseline x-ray opacification and
minimization variables.
bOutcomes for pleural fluid volume
reported as mean (SD) volume in
milliliters.
c Outcomes for chest radiograph
opacity reported as mean (SD)
percentage of hemithorax occupied.
d Pain outcomes reported as median
(interquartile range) score in
millimeters on the VAS pain scale.
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ferent results from per-protocol and ITT analyses (Figure 2),
which imply that if talc is successfully administered via a
smaller tube, it results in reasonable pleurodesis success.
Should it be the case, this represents a significant disadvan-
tage of smaller-tube treatment. The reasons for these clini-
cally important difference are not clear; it is unlikely, how-
Table 5. Safety BloodMeasurement Outcomes
Outcomes by Treatment Group Change, Mean (SD)
Treatment Effect, Mean
Difference (95% CI) P Value
Change in hemoglobin,
day 0 to day 2, g/dL
Chest tube size
24F (n=34) −0.3 (0.6)
0.1 (−0.3 to 0.5) .52
12F (n=25) −0.4 (0.7)
Analgesia
Opiates (n=106) −0.4 (1.0)
−0.1 (−0.4 to 0.2) .41
NSAIDs (n=103) −0.7 (1.2)
Change in creatinine,
day 0 to day 2, mg/dL
Chest tube size
24F (n=34) −0.08 (0.24)
4 (−7 to 15) .45
12F (n=25) 0 (0.10)
Analgesia
Opiates (n=103) −2 (12)
9 (4 to 15) .001
NSAIDs (n = 104) 7 (26)
Change in urea nitrogen,
day 0 to hospital discharge, mg/dL
Chest tube size
24F (n=32) 2.8 (12.9)
−3.6 (−8.4 to 1.1) .12
12F (n=22) 0.3 (5.9)
Analgesia
Opiates (n=70) 0.6 (8.4)
1.1 (−1.7 to 3.6) .47
NSAIDs (n=54) 2.5 (10.6) Abbreviation: NSAIDs, nonsteroidal
anti-inflammatory drugs.
Table 4. Serious, Nonserious, and Tube Insertion–Related Adverse Events
Events by Treatment Group
No. (%) of Patients
With Event
Treatment Effect, Odds Ratio
(95% CI) P Value
Serious adverse events
Chest tube size (n=57)
24F 6 (11)
0.80 (0.2-2.9) .73
12F 5 (9)
Analgesia (n=160)
Opiates 13 (8)
1.1 (0.5-2.4) .84
NSAIDs 14 (9)
Nonserious adverse events
Chest tube size (n=57)
24F 32 (56)
1.1 (0.5-2.3) .84
12F 33 (58)
Analgesia (n=160)
Opiates 72 (45)
0.7 (0.4-1.1) .11
NSAIDs 60 (38)
Complications during tube insertiona
Chest tube size
24F (n=56) 8 (14)
1.9 (0.7-5.1) .20
12F (n=55) 13 (24)
Analgesia
Opiates (n=158) 20 (13)
1.2 (0.6-2.4) .56
NSAIDs (n=156) 22 (14)
Abbreviation: NSAIDs, nonsteroidal
anti-inflammatory drugs.
a Tube insertion complication overall
frequencies were bleeding, n=5;
repeat insertion required, n=11;
pleural space not entered, n=2;
syncope, n=5; and other, n=23.
Whenmore than 1 complication
occurred in a single patient, it was
recorded as a single complication.
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ever, to be related to insertion technique and experience
with chest tubes, as all centers participating in this study
have established pleural intervention practices, and proto-
colized management (including the use of intrapleural
flushes with smaller tubes) was undertaken.
Although some of the observed difference in pleurodesis
efficacy may have been due to the use of thoracoscopic talc
poudrage (in which talc is administered after full drainage of
the chest in a single procedure), patients undergoing thoraco-
scopic procedures were excluded from the primary data
analysis of chest tube size for this reason, and therefore, the
potential reduction in pleurodesis efficacy with smaller tubes
appears to be real. Randomization in this study was mini-
mized by thoracoscopic procedure, ensuring that pre hoc
subgroup analysis was feasible. There was no evidence of an
advantage to thoracoscopically delivered talc, although this
was not a primary randomized study assessing this treatment
mode, and ongoing trials should provide valuable informa-
tion on this aspect of care.21
Larger tubeswereassociatedwith significantlymorepain;
whether this is related to the size of the traumatic injury re-
quired for chest tube insertion or related to insertion tech-
nique is not clear from our data. As all larger tubes were in-
serted using the blunt dissection technique and all smaller
tubes inserted using the guide-wire technique, we were un-
able to address this issue.Whether using the guide-wire tech-
nique reduces pain but allows safer insertion of larger tubes
requires further investigation.
There are important limitations to this study. First, this
trial was not clinician- and patient-blinded, using “masked”
drains and a double-dummy, double-placebo analgesic
design, and this may have introduced bias in the assessment
of pain. Second, as a consequence of recruiting patients
undergoing thoracoscopy (in whom only a large-bore tube
can be used), the number of patients in the primary compari-
son of chest tube size for pleurodesis efficacy was limited.
Thus, it is likely that this analysis is underpowered, but it
remains the largest study to directly address this question.
Third, the power calculation for pain was based on a non-
pleurodesis model of acute pain using similar assessment
methods18; data on the pain caused by pleurodesis using
these methods were not available during trial planning, and
this limitation does not affect the validity of comparative
treatment analyses for this study. Fourth, the noninferiority
margin of 15% was based on a survey of clinical expert opin-
ion rather than on empirical data, which were not available at
the time of trial planning.
On the basis of this randomized trial,what should nowbe
the recommendedmethodof talc pleurodesis? There appears
to beno advantage toNSAID-based analgesia but no reason to
avoiduseof thesedrugs forpostpleurodesispain.Thus, forpa-
tients at risk of opiate toxicity,NSAID-based analgesia is a rea-
sonable treatment alternative with evidence of noninferior
pleurodesis efficacy but modest increased use of rescue an-
algesia.There isnowanargument for theuseof large-borechest
tubes for malignant pleural effusion pleurodesis on the basis
of data from this trial. Although larger tubes were associated
withmore pain than smaller tubes, thiswas not clinically sig-
nificant, and it cannot now be assumed that 12F tubes are as
effective as 24F tubes in providing long-term fluid control af-
ter pleurodesis, which is the treatment intent. It appears that
there are no clinically significant advantages of use of smaller
tubes for malignant pleural effusion pleurodesis and the po-
tential to reduce pleurodesis success, despite their current
widespread use and the recommendations in national guide-
lines. These data highlight the need for adequately powered
studiesaddressingspecific clinicalmanagement issues incom-
mon pleural diseases.
Conclusions
Amongpatientswithmalignant pleural effusions undergoing
pleurodesis, the use of NSAIDs compared with opiates re-
sulted in no significant difference in pain scores but was as-
sociated with more use of rescue medication while the chest
tube was in place; however, NSAID use also resulted in non-
inferior rates of pleurodesis efficacy at 3 months. Among pa-
tients who did not undergo thoracoscopy, placement of 12F
chest tubescomparedwith24Fchest tubeswasassociatedwith
astatistically significantbutclinicallymodest reduction inpain
scores and failed tomeet noninferiority criteria for pleurode-
sis efficacy.These results challenge current guidelines that ad-
vocate avoidance of NSAIDs and use of small chest tubes.
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